Researchers have found that people with 2 copies of the APOE4 gene is more than a risk factor – it is now considered an underlying cause of Alzheimer’s Disease. Prior to the research’s finding published in May, scientists knew the gene APOE4 increased risk. Although...
Earlier this year, leqembi (a drug that slows memory decline for those in the early stages of Alzheimer’s Disease by targeting the amyloid protein, usually common with those inflicted with Alzheimer’s as it begins to form) was approved by both FDA and CMS (governmental assistance...
A milestone event in the fight against Alzheimer’s Disease occurred on July 6 when the FDA gave approval for a drug (Leqembi) that not only slows memory loss for those with Alzheimer’s Disease, but it was granted funding approval by the Centers for Medicare &...
The FDA has recently approved the medication Aducanumab (which is to be given by infusion every four weeks) that studies have shown to slow the decline of cognitive and functional ability of patients (particularly if in the early stages after a diagnosis or those with...
The U.S. National Institute of Aging (NIA) is giving the University of California, Berkley a five year grant expected to total $47 million to determine whether lifestyle changes will reduce the risk of developing Alzheimer’s disease. The study will be used to determine if lifestyle interventions...
